Clinical trial
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination…
NCT00454116 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00454116 |
|---|---|
| Title | A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
| Official title | A Phase II, Double Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Oxaliplatin and Fluoropyrimidine Containing… |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Vandetanib, FOLFIRI |
| Enrollment | 106 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2008 |
| Completion | Nov 1, 2009 |
| First posted | Mar 30, 2007 |
| Last update posted | Oct 7, 2016 |
| Countries | Argentina, Norway, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: